Xenomics CEO Discusses Company's Innovative DNA Diagnostic Technology in Online Interview...

LOS ANGELES -- SmallcapInsights.com, http://www.SmallcapInsights.com, the online source for exclusive commentary, research, interviews and other key investor information, has announced the availability of an online interview with Dr. Randy White, CEO of Xenomics (OTCBB:XNOM), a molecular diagnostics

In the audio interview, Dr. White provides an overview of Xenomics' business strategy, proprietary intellectual property portfolio and patents regarding trans-renal DNA. To integrate the Xenomics testing and detection methods into existing laboratories, Dr. White explains, "Our technology is completely patented, and no one can develop tests using trans-renal DNA other than us, so we've decided to create reagent systems that work on the existing instruments that are in the laboratory."

Dr. White also discusses recent medical findings in the fields of HIV detection and transplant monitoring, as well as potential marketplaces for the Xenomics solutions and future developments. The streaming audio interview can be accessed at http://www.SmallcapInsights.com. Registration to listen to the interview is free.

About Xenomics, Inc.

Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using trans-renal DNA (Tr-DNA). Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. Scientists from Xenomics were the first to report that fragments of DNA from normal cell death cross the kidney barrier and can be detected in urine. The Company believes that its technology will open significant new markets in the molecular diagnostics field. Xenomics has three issued U.S. patents covering different applications of the technology for molecular diagnostics and genetic testing and a pending European patent for the same applications. The Company has organized a joint venture to conduct research on infectious disease detection with the National Institute for Infectious Diseases (Instituto Nazionale per le Malattie Infettive "Lazarus Spallanzani") in Rome, in the form of a new R&D company called SpaXen Italia, S.R.L. For more information, please visit http://xenomics.com. For more investor-specific information, including daily and historical Company stock quote data and recent news releases, please visit http://www.trilogy-capital.com/tcp/xenomics. To read or download the Company's Investor Fact Sheet visit http://www.trilogy-capital.com/tcp/xenomics/factsheet.html. To view an online video about Xenomics technology and products, visit http://www.trilogy-capital.com/tcp/xenomics/video.html.

About SmallcapInsights.com

SmallcapInsights.com provides exclusive commentary, research, interviews and other information about the smallcap investment marketplace. SmallcapInsights.com strives to provide investors with information and research-based data regarding important individual companies and overall marketplace trends. Resources available on SmallcapInsights.com include audio interviews with corporate leaders and respected commentators, as well as technical white papers and other forms of market and investment analysis. It is located at http://www.SmallcapInsights.com.

Forward-Looking Statements

Statements made on SmallcapInsights.com may contain forward-looking statements made by senior management of the companies presented here that involve risks and uncertainties, such as statements about plans, objectives, expectations, assumptions or future events. These statements involve estimates, assumptions, known and unknown risks, uncertainties and performances, or achievements expressed or implied by the forward-looking statements. Actual future results and trends may differ materially from those made in -- or suggested by -- statements presented here due to a variety of factors. Consequently, you should not place undue reliance on any forward-looking statements made here. Many of these and other risks and uncertainties are discussed in greater detail in recent filings with the Securities Exchange Commission for the companies that are present by SmallcapInsights.com.

Compensation and Other Disclosures

SmallcapInsights.com is a wholly-owned subsidiary of Trilogy Capital Partners, Inc. Trilogy Capital Partners provides investor relations services to public companies. The companies presented by SmallcapInsights.com are usually clients of Trilogy Capital Partners and compensate Trilogy Capital Partners for these services, including cash compensation and equity securities. In addition, Trilogy Capital Partners and its affiliates may own securities of the presenting companies, and may from time to time purchase and sell securities of these companies in the open market or in private transactions. Trilogy receives compensation from Xenomics of $10,000 per month through January 2006 and thereafter for so long as Trilogy is retained to provide investor relations services.

The Company issued Trilogy warrants to purchase 1,000,000 shares of Common Stock of the Company at an exercise price of $2.95 per share (the "Warrants"). The Warrants issued to Trilogy are exercisable upon issuance and expire on January 10, 2008. In the event the Company proposes to register any of its Common Stock under the Securities Act of 1933 for sale in connection with a public offering of Common Stock, the Company will give written notice to Trilogy and will include in such registration statement any of the shares of Common Stock underlying the Warrants which Trilogy may request be included. The offer and sale of these securities was made in reliance on Section 4(2) of the Securities Act of 1933, as amended. The offer and sale of the Warrants did not involve a public offering.